Home > Publications Database > Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets? > print

001     139570
005     20240321220637.0
024 7 _ |a 0006-3002
|2 ISSN
024 7 _ |a 10.1016/j.bbamcr.2017.06.007
|2 doi
024 7 _ |a pmid:28624439
|2 pmid
024 7 _ |a 0167-4889
|2 ISSN
024 7 _ |a 1879-2596
|2 ISSN
024 7 _ |a altmetric:80955176
|2 altmetric
037 _ _ |a DZNE-2020-05892
041 _ _ |a English
082 _ _ |a 570
100 1 _ |a Mentrup, Torben
|b 0
245 _ _ |a Signal peptide peptidase and SPP-like proteases - Possible therapeutic targets?
260 _ _ |a Amsterdam [u.a.]
|c 2017
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2017-11-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1710172076_27993
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Signal peptide peptidase (SPP) and the four homologous SPP-like proteases SPPL2a, SPPL2b, SPPL2c and SPPL3 are GxGD-type intramembrane-cleaving proteases (I-CLIPs). In addition to divergent subcellular localisations, distinct differences in the mechanistic properties and substrate requirements of individual family members have been unravelled. SPP/SPPL proteases employ a catalytic mechanism related to that of the γ-secretase complex. Nevertheless, differential targeting of SPP/SPPL proteases and γ-secretase by inhibitors has been demonstrated. Furthermore, also within the SPP/SPPL family significant differences in the sensitivity to currently available inhibitory compounds have been reported. Though far from complete, our knowledge on pathophysiological functions of SPP/SPPL proteases, in particular based on studies in mice, has been significantly increased over the last years. Based on this, inhibition of distinct SPP/SPPL proteases has been proposed as a novel therapeutic concept e.g. for the treatment of autoimmunity and viral or protozoal infections, as we will discuss in this review. This article is part of a Special Issue entitled: Proteolysis as a Regulatory Event in Pathophysiology edited by Stefan Rose-John.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
542 _ _ |i 2017-11-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2018-11-01
|2 Crossref
|u http://www.elsevier.com/open-access/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Membrane Proteins
|2 NLM Chemicals
650 _ 7 |a Peptides
|2 NLM Chemicals
650 _ 7 |a dermcidin
|2 NLM Chemicals
650 _ 7 |a Amyloid Precursor Protein Secretases
|0 EC 3.4.-
|2 NLM Chemicals
650 _ 7 |a Aspartic Acid Endopeptidases
|0 EC 3.4.23.-
|2 NLM Chemicals
650 _ 7 |a SPPL2a protein, human
|0 EC 3.4.23.-
|2 NLM Chemicals
650 _ 7 |a SPPL2b protein, human
|0 EC 3.4.23.-
|2 NLM Chemicals
650 _ 2 |a Amino Acid Sequence: genetics
|2 MeSH
650 _ 2 |a Amyloid Precursor Protein Secretases: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Amyloid Precursor Protein Secretases: genetics
|2 MeSH
650 _ 2 |a Aspartic Acid Endopeptidases: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Aspartic Acid Endopeptidases: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Membrane Proteins: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Membrane Proteins: genetics
|2 MeSH
650 _ 2 |a Peptides: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Peptides: genetics
|2 MeSH
650 _ 2 |a Peptides: metabolism
|2 MeSH
650 _ 2 |a Proteolysis
|2 MeSH
650 _ 2 |a Substrate Specificity
|2 MeSH
700 1 _ |a Loock, Ann-Christine
|b 1
700 1 _ |a Fluhrer, Regina
|0 P:(DE-2719)2000007
|b 2
|u dzne
700 1 _ |a Schröder, Bernd
|0 P:(DE-HGF)0
|b 3
|e Corresponding author
773 1 8 |a 10.1016/j.bbamcr.2017.06.007
|b : Elsevier BV, 2017-11-01
|n 11
|p 2169-2182
|3 journal-article
|2 Crossref
|t Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
|v 1864
|y 2017
|x 0167-4889
773 _ _ |a 10.1016/j.bbamcr.2017.06.007
|g Vol. 1864, no. 11 Pt B, p. 2169 - 2182
|0 PERI:(DE-600)2209512-3
|n 11
|q 1864:11 Pt B<2169 - 2182
|p 2169-2182
|t Biochimica et biophysica acta / Molecular cell research
|v 1864
|y 2017
|x 0167-4889
856 4 _ |u https://pub.dzne.de/record/139570/files/DZNE-2020-05892_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/139570/files/DZNE-2020-05892_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:139570
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2000007
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-11
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BBA-MOL CELL RES : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BBA-MOL CELL RES : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1110000-2
|k AG Fluhrer
|l Signal Peptide Peptidases as Models for γ-Secretase
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1110000-2
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21